Carl Zeiss Meditec AG reaffirms its annual target
(firmenpresse) - (DGAP-Media / 14.08.2013 / 07:04)
Carl Zeiss Meditec AG reaffirms its annual targetJENA, 14 August 2013
Revenue reached EUR 649 million / EBIT margin increased to 14.3 percent /
Forecast for whole year confirmed
Facing a slight downturn in the overall market, Medical technology provider
Carl Zeiss Meditec AG raised its revenue by 2.9 percent to EUR 649 million
(previous year: EUR 630.8 million) in the first nine months of financial
year 2011/2012. In the first nine months of the current financial year, the
Company increased its earnings before interest and taxes (EBIT) from EUR
88.6 million to EUR 92.5 million and confirms its revenue forecast for the
whole year.
'Thanks to our balanced global presence we achieved once again a solid
result despite disparate development in the strategic business units and we
consider ourselves to be well on the way for achieving our goals in the
current financial year', says Dr. Ludwin Monz, President and CEO of Carl
Zeiss Meditec AG. The Company is predicting sales totaling between EUR 880
and 910 million in the current financial year 2012/2013.
According to Ludwin Monz, the expansion of the solutions business will have
a positive effect also beyond the end of the current financial year.
However, the Company expects continued competitive pressure in parts of the
ophthalmic market and lower growth rates in microsurgery which may tend to
lead to a lower gross margin. 'Even in view of the economic downturns we
continue to adhere to our targets for 2015. We want to increase the
percentage of case-number-dependent products and services in consolidated
revenue to 25 percent and to achieve an EBIT margin of 15 percent',
comments Ludwin Monz. In the first nine months of the current financial
year EBIT margin was 14.3 percent and thus 0.3 percentage points higher
than in the same period of the previous year. Thanks to the positive
financial result earnings per share moved sharply higher to EUR 0.81
(previous year: EUR 0.65).
Key figures by region and business units at a glance
In the first nine months the three strategic business units showed
different dynamics. After a weak start at the beginning of the year
Ophthalmic Systems held their ground again. Even in a continued tense
competitive situation, a slight revenue growth of 0.2 percent from EUR
266.3 million to EUR 266.8 million could be achieved. Compared to the
previous year, growth in Microsurgery was significantly more moderate and
drew closer to the generally more restrained market development. The
revenue rose by 1.7 percent to EUR 289.5 million compared to EUR 284.7
million in the previous year. The Company benefited once again from the
continuing development in the business with intraocular lenses. In the
Surgical Ophthalmology business unit, revenue increased by 16.2 percent to
EUR 92.7 million. In the previous year the figure was EUR 79.8 million.
The three reporting regions recorded comparable growth. In the EMEA region
(Europe, Middle East, Africa) revenues were up by 3.0 per cent. As in the
first months of the financial year, the declines in Southern European
countries were once again overcompensated for by the continued positive
development of business in Germany, the persistently strong growth in
Russia and the good growth overall in the Middle East. The Americas region
grew by 2.8 percent. Carl Zeiss Meditec recorded excellent growth rates in
South America, while the U.S. market - in spite of a positive third quarter
- remained on a slight downward trend. The Asia/Pacific (APAC) region
recorded revenue growth of 2.9 percent, whereas growth was reduced once
again by currency effects as in the first six months. Adjusted for currency
effects, growth was 9.1 percent.
'Even if market conditions are not easy, we consider our prospects of
future business development to be good', says Ludwin Monz. 'In the coming
months it will be absolutely essential to generate growth through
innovations in Ophthalmic Systems, to leverage growth potential in
Microsurgery facing a restrained market development and to continue the
very positive development of Surgical Ophthalmology. Our high levels of R&D
investment, which are tailored to sustainability, a deliberate cost
management and the well balanced position of our business worldwide shall
continue to be the basis of a sound development well into the future.'
Revenue by strategic business unit
Figures in EUR '000 9 Months 2011/ 9 Months 2012/ Change from previousRevenue by region
2012 2013 year
Ophthalmic Systems 266,308 266,826 + 0.2%
Surgical 79,816 92,735 + 16.2%
Ophthalmology
Microsurgery 284,693 289,481 + 1.7%
Figures in EUR 9 Months 2011/ 9 Months 2012/ Change from previousPress contact:
'000 2012 2013 year
EMEA 217,653 224,142 + 3.0%
Americas 215,034 221,119 + 2.8%
Asia/Pacific 198,130 203,781 + 2.9%
region
Jann Gerrit Ohlendorf, Director Corporate Communications, Carl Zeiss
Meditec AG
Phone 03641 220-331, E-Mail: press.meditec(at)zeiss.com
Contact for investors:
Henriette Meyer, Director Investor Relations, Carl Zeiss Meditec AG
Phone 03641 220-106, E-Mail: investors.meditec(at)zeiss.com
www.meditec.zeiss.de/presse
End of Media Release
---------------------------------------------------------------------
Issuer: Carl Zeiss Meditec AG
Key word(s): Enterprise
14.08.2013 Dissemination of a Press Release, transmitted by DGAP - a
company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: Carl Zeiss Meditec AG
Göschwitzer Str. 51-52
07745 Jena
Germany
Phone: +49 (0)3641 220-0
Fax: +49 (0)3641 220-6808
E-mail: investors(at)meditec.zeiss.com
Internet: www.zeiss.de
ISIN: DE0005313704
WKN: 531370
Listed: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, Hamburg, Hannover,
München, Stuttgart
End of News DGAP-Media
---------------------------------------------------------------------
225739 14.08.2013
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 14.08.2013 - 07:04 Uhr
Sprache: Deutsch
News-ID 287469
Anzahl Zeichen: 5768
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 297 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Carl Zeiss Meditec AG reaffirms its annual target"
steht unter der journalistisch-redaktionellen Verantwortung von
Carl Zeiss Meditec AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
